M Partners analyst Paul Piotrowski maintained a Buy rating on Trulieve Cannabis (OTC:TCNNF) on Thursday, setting a price target of C$40, which is approximately 28.04% above the present share price of $23.68.
Piotrowski expects Trulieve Cannabis to post earnings per share (EPS) of $0.06 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Trulieve Cannabis, with an average price target of $35.1.
The analysts price targets range from a high of $45 to a low of $27.29.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $120.76 million and a net profit of $37.5 million. The company's market cap is $2.68 billion.
According to TipRanks.com, M Partners analyst Paul Piotrowski is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.8% and a 61.11% success rate.
Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.